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A B S T R A C TBackground: The progression of hepatitis C virus (HCV) disease
usually occurs over a 10-year period. HCV-related complications as
well as the highly debilitating effects on patients represent a signiﬁ-
cant item of expenditure for the National Health Service. Early
detection of HCV infection is an excellent opportunity to improve
patients’ quality of life and to rationalize resource allocation. Objec-
tive: The aim of this study was to provide a cost-effectiveness
evaluation of an anti-HCV screening program in the Italian National
Health Service perspective. Methods: We built a Markov model made
up of two arms. The ‘‘Test Strategy’’ arm involves a screening program
based on the enzyme immunoassay for detection of antibodies as
ﬁrst-level test and the research of HCV RNA as second-level detection;
patients with positive test results are treated with peg-interferon alfa
in combination with ribavirine. Parameters were derived from the
literature and validated through experts’ opinion. Costs and beneﬁtssee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.07.005
i@rm.unicatt.it.
ndence to: Matteo Ruggeri, Faculty of Economics, Cwere discounted by 3.5%. Results were expressed as cost/quality-
adjusted life-year (QALY) gained through the screening program com-
pared with the treatment of symptomatic patients. Deterministic and
probabilistic sensitivity analysis was performed. Results: The incremen-
tal cost-effectiveness ratio of the ‘‘Test Strategy’’ is €5171/QALY, deﬁn-
itively below the cost/QALY of other approved treatments in Italy. Model
results turned out as sensitive to the age of the target population, the
prevalence of HCV infection, and the time horizon adopted. Conclu-
sions: The anti-HCV screening program is a valid health-related invest-
ment improving patients’ quality of life and survival with an acceptable
expenditure increase for the National Health Service.
Keywords: cost-effectiveness, Italy, liver disease, Markov model.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Viral hepatitis is a chronic condition with a latent, nonlinear
disease progression. Hepatitis C virus (HCV) disease can remain
asymptomatic for decades and resolves spontaneously only in
exceptional cases. The disease normally takes over a decade to
progress, although this may be accelerated by the presence of
various cofactors including alcohol use, diabetes mellitus (for
which HCV is a risk factor), the age at which the disease was
developed, and coinfection with HIV or other hepatotropic
viruses. Between 10% and 40% of patients with chronic HCV
infection will develop cirrhosis, depending on the occurrence of
these cofactors. The annual incidence of death due to cirrhosis
complications is around 4%, while the annual incidence of
hepatocarcinoma (HCC) among patients with chronic HCV infec-
tion is 1% to 5%. Patients with HCC have a 33% chance of
surviving beyond 1 year after its onset [1].
Early diagnosis following a screening test for chronic hepatitis
is an effective tool for the prompt treatment of HCV infection,
stopping the progression of any liver disease. Numerous studies
have been conducted in recent years to investigate the cost-
effectiveness ratio of screening for viral hepatitis. Many of these
studies have used decisional models because these tools are well-
suited to the design of early diagnosis programs, which usually
require considerable investment in the present but pay back theirbeneﬁts to health many years later. A recent systematic review
[2] summarized the results of seven studies about hepatitis C
screening programs carried out in France, Great Britain, and the
United Kingdom on subgroups of patients. The incremental cost-
effectiveness ratio (ICER) of screening compared with treatment
of symptomatic patients was found to range between €3,900 and
€243,700 per life-year gained, or €18,000 and €1,151,000 per
quality-adjusted life-year (QALY) gained. The authors concluded
that screening was cost-effective in populations with a high
prevalence of HCV infection but excessively costly in populations
with a low prevalence.
The purpose of this study was to evaluate the cost-
effectiveness of a screening strategy aimed at identifying HCV-
positive patients in comparison with the treatment of patients
who have developed cirrhosis or HCC following undiagnosed
chronic hepatitis.Methods
Model Structure
We studied HCV disease progression up to death, simulating the
observation of a cohort of 100,000 individuals from the generalociety for Pharmacoeconomics and Outcomes Research (ISPOR).
atholic University of Sacred Heart, l.go F.Vito 1, Rome 00168, Italy.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 6 5 – 9 7 2966population by means of the application of a two-arm Markov
model:1. The screening-strategy arm involves two screening tests
administered to individuals from the general population and
the subsequent treatment of subjects testing positive.2. The no-screening-strategy arm involves the treatment of
patients with cirrhosis or HCC.
The Markov model enables the simulation of the disease
progression as a result of various screening and treatment
strategies administered in line with the disease stage. It therefore
enables the evaluation and long-term projection of the beneﬁts of
early diagnosis in terms of survival, quality of life, and cost-
effectiveness. This allows monitoring disease progression and
relative mortality, morbidity, and costing continuously and
dynamically, even considering cohorts with different character-
istics [3,4]. The model and the parameters necessary to recon-
struct the natural history of the disease were developed through
a literature review using the Medline search engine and relying
on the consultation of a panel of experts in the ﬁeld of
hepatology.
Figure 1 shows the Markov model constructed to simulate the
natural history of HCC and cirrhosis and how it changes as a
consequence of the treatment adopted. The time horizon con-
sidered was lifetime, with a 1-year cycle length. Also a half-cycle
correction was introduced, reducing therefore the relevant time
of analysis to 6 months, given that individuals on average change
their state of health within shorter periods of time.
Chronic HCV infection can lead to the development of com-
pensated or decompensated cirrhosis and, either directly or
following further progression, HCC. Decompensated cirrhosis
and HCC can be treated with liver transplantation. Any of these
health conditions can cause the patient’s death. The transition
probabilities used to populate the model were found in the
literature. Table 1 of the Appendix in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2013.07.005 reports the
transition probabilities used to populate the model, including
the values used for the base case and for the sensitivity analysis.
We assumed that the mortality rate of people affected by chronic
HCV infection coincides with the clustered-by-age probability ofFig. 1 – Model structure. HCC, hepatocadeath due to causes other than disease, provided in the Italian
Institute of Statistics tables [5]. Instead, the probability of death
for cirrhosis, liver transplant, and HCC was taken from the
literature [6].
Screening Strategies
Identiﬁcation of target population
An anti-HCV screening test is assumed to be administrated to
Italian healthy or asymptomatic people who are aged 35 years or
older. The hypothetical cohort is composed of four age groups:
35- to 44-year-old people, 45- to 54-year-old people, 55-to 64-year-
old people, people older than 65 years. The prevalence of HCV
infection within this population is strongly affected by age and
that is why we split it into age groups. Prevalence data for age
groups were derived from Ansaldi et al. [7]. Values are reported in
Table 1. The percentage of individuals belonging to each age
category has been estimated on the basis of tables published by
the Italian Institute of Statistics [8].
In the base case, the study population is composed of
individuals from each age group, while a heterogeneity analysis
was carried out to consider the impact of age on model results.
The size of the cohort corresponds to that of the population
usually assisted by a local health authority, coherently with the
relative age group composition. To take into account the different
prevalence of disease in geographical areas and in particular the
North-South gradient [9,10], we stratiﬁed the deterministic ana-
lysis in three scenarios, and used data referring to the whole
Italian territory for the base case [7]. This issue is discussed in
depth later.
Testing of disease state
In the ﬁrst model cycle, 100,000 hypothetical individuals from the
general population undergo HCV screening. They are either
healthy or asymptomatic. The cohort is composed of people aged
35 to 65 years. The composition of the sample in terms of age has
been derived from tables provided yearly by the Italian Institute
of Statistics [8]. From the second cycle on, only the proportion of
people affected by HCV infection has been considered. This
number is determined by the prevalence of hepatitis and thus
is the same in the no-screening arm. This expedient has beenrcinoma; HCV, hepatitis C virus.
Table 1 – HCV prevalence data.
Base case (Italy)
Age (y) Mean prevalence Estimated standard error Alpha Beta Distribution Source
15–30 0.02 0.004 18.42 1023.16 Beta [7]
31–45 0.06 0.011 28.88 457.03 Beta [7]
46–60 0.07 0.015 19.90 270.55 Beta [7]
460 0.05 0.017 8.90 163.13 Beta [7]
HCV, hepatitis C virus.
Table 2 – Efﬁcacy of HCV pharmacological treat-
ments characterized by genotype [12].
Treatment Efﬁcacy Distribution Weighted
average*
Peg-2a þ ribavirin 0.48
HCV Gen 2/3 0.76 Beta
HCV Gen 1/4 0.46 Beta
Peg-2b þ ribavirin
HCV Gen 2/3 0.61 Beta
HCV Gen 1/4 0.36 Beta
Gen, genotype; HCV, hepatitis C virus.
 Value weighted on the basis of the prevalence of each genotype.
Please see Table 3.
Table 3 – Distribution of HCV genotypes in Italy.
Genotype Prevalence
(%)
Distribution Source
G1 66 Deterministic value [7]
G2 20 Deterministic value [7]
G3 6 Deterministic value [7]
G4 8 Deterministic value [7]
HCV, hepatitis C virus.
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also involve the administration of the test to the proportion of
healthy individuals. The cost of negative test results has been
spread across patients with positive test results in the computa-
tion of the use of resources. In the subsequent cycle, individuals
testing positive receive the pharmacological treatment indicated
as the gold standard by international guidelines, with the aim of
stopping disease progression. After treatment, patients progress
to subsequent stages if they do not respond to the pharmaceut-
ical treatment.
In this arm, the ﬁrst-level screening test is the enzyme
immunoassay for anti-HCV antibodies [1]. The presence of anti-
bodies reveals that the patient has been infected with HCV, but it
does not establish when the infection took place, nor if it is still
active. As a matter of fact, this test result will remain positive
forever even in patients who have recovered, either spontane-
ously or following treatment. It thus has the drawback of a
signiﬁcant number of false positives (speciﬁcity ¼ 90%) [11].
While negative results do not need further investigations, pos-
itive test results deserve a more accurate analysis, to rule out
patients who have already eradicated the HCV virus either
spontaneously or thanks to some previous treatment. For this
reason, we postulated that those testing positive on the ﬁrst test
would undergo a more speciﬁc test, HCV RNA detection by
polymerase chain reaction. This test conﬁrms or excludes the
presence of the virus in the blood and thus the patient’s real
chronic disease status [1]. Therefore, an accuracy of 100% was
assumed for the combination of the two diagnostic tests. Patients
with only positive test results are included in the model. Patients
with negative test results and false-negative results do not enter
the model.Treatment of Patients with Positive Test Results
For chronic HCV infection, the duration and efﬁcacy of pharma-
cological treatments correspond to the mean duration and
efﬁcacy indicated for each genotype, weighted according to the
genotype distribution [7]. Variability in the duration and efﬁcacy
of treatments in correlation with the genotype was explored in
the sensitivity analysis. The selected treatments for chronic HCV
infection were peg-interferon alfa 2a (PEG-IFN alfa 2a) and peg-
interferon alfa 2b (PEG-IFN alfa 2b), both in combination with
ribavirin [11]. We assumed that drug-related adverse events were
managed through dose reductions. The occurrence of ﬂu-like
symptoms in patients undergoing combination therapy, how-
ever, has been considered by attributing a utility coefﬁcient
smaller than one in these patients.
The theoretical efﬁcacy of the HCV is reported in Table 2. For a
more in-depth analysis, refer to the section concerning the
management of patients with HCV infection. The HCV genotype
distribution used to populate the model was that observed in a
sample of the Italian population, and is reported in Table 3.
Patients receive pharmacological treatment during the Mar-
kov cycle following the screening tests. They pass from chronichepatitis to subsequent stages of the disease if the treatment is
ineffective. Patients whose disease does not progress undergo the
following treatments in the subsequent cycles: hepatology consultations two to three times a year;
 laboratory tests (complete blood cell count, liver function,
protein electrophoresis) two to three times a year;
 abdominal ultrasound once a year or every 2 years;
 HCV RNA test once a year or every 2 years; and
 liver ultrasound once every 2 to 3 years.
HCV treatment data were found in the literature and validated
through experts’ opinion.
No-Screening Arm
Patients enrolled in the no-screening arm do not undergo screen-
ing and enter the model if they get affected by an HCV infection.
Hence, the number of individuals in this arm has been deter-
mined by applying the prevalence rate to a population of 100,000
individuals, exactly as in the screening arm. Not being these
patients screened, they receive their ﬁrst treatment only in the
states of cirrhosis or HCC [12]. In fact, most of the patients do not
show any symptom at the occurrence of the disease. It has been
estimated that in the absence of alcohol abuse, drug addiction, or
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to the development of cirrhosis. Hence, people who are not aware
of having the infection will hardly realize the progression of
chronic hepatitis. They will discover their disease after 25 to 30
years, because of the sudden appearance of a complication
related to cirrhosis or, speciﬁcally, because of the development
of liver cancer, which represents the major complication and the
most frequent cause of death of patients with chronic hepatitis C
[13]. Patients in the no-screening arm are assumed to remain
asymptomatic until the development of either cirrhosis or HCC.
People affected by HCV infection and cirrhosis are treated with
PEG-IFN and ribavirine but even if the therapy is effective, they
cannot achieve the state of virological response [14]. The effec-
tiveness of drugs is lower in patients with cirrhosis. The treat-
ment, in this case, is aimed at stopping or slowing down disease
progression. It prevents people from developing decompensation.
Treatment of patients with decompensated cirrhosis involves
hospitalization, and in the event of a positive risk/beneﬁt ratio,
liver transplantation. Patients with HCC undergo chemotherapy
aimed at stopping disease progression, and if necessary liver
transplantation, again on the basis of the risk/beneﬁt ratio [1].Resource Cost Calculation
The cost of the resources used for the implementation of the two
arms (treatments, clinical examinations, diagnostic examinations,
routine admissions, day hospital, and outpatient appointments)
was calculated from the perspective of the Italian National Health
Service (INHS). The costs of pharmacological treatments were
calculated on the basis of their label price, as published by the
Italian Agency of Medicine, without considering the 5% discounts
required by the agency [15]. This value was calculated by adding
the distribution margins (wholesaler þ pharmacist) and value
added tax to the ex-factory price. The INHS reimburses the entire
price to pharmacists, net of a percentage corresponding to the
discount that the pharmacist must apply to the INHS. The priceTable 4 – Cost values used in the base case.
Outpatient
Anti-HCV screening
First-level screening (antibodies)
Immunoblotting
Chronic HCV
Hepatology consultation*
Laboratory tests (complete blood cell count, liver function, protein
electrophoresis)*
Abdominal ultrasound
Drug combination therapy
Compensated cirrhosis
Abdominal echotomography*
Esophageal duodenoscopy (OGDS)*
Decompensated cirrhosis
HCV-RNA*
Esofagogastroduodenoscopy (EGDS)*
Hepatic ecography*
Hepatocarcinoma
Tumor markers*
Computed tomography*
Liver transplantation
DRG, Diagnosis-Related Group; HCV, hepatitis C virus.
 Annual cost.considered in this analysis is the one actually paid by the INHS,
taken from the pharmaceutical formulary. In the base case, an
average price was used as unit cost and the duration of treatments
was established according to the prevalence of genotypes.
The costs of specialist outpatient services were taken from the
maximum national charges established by the Ministerial Decree
of September 12, 2006—“Recognition and ﬁrst update of the
maximum charges for the remuneration of health care serv-
ices”— published in Ofﬁcial Gazette no. 289 of December 13, 2006,
which updated the maximum reference charges for the remu-
neration of health care services and procedures payable by the
INHS, pursuant to article 1, subsection 170 of Law no. 311 of
December 30, 2004 [16]. Consumption data of resources related to
hospitalization for cirrhosis, HCC, or liver transplant were taken
from the current edition of the DRG (Diagnosis Related Group)
charges, updated to 2009 [17]. Costs for the treatment of cirrhosis
were also referred to experts’ opinion. Experts involved in this
study are permanent members of the Workshop of Economics
and Drugs in Hepatology. The values reported by Sullivan et al.
[12] were used to compute the posttransplant costs after hospital-
ization. Table 4 reports the costs used to populate the HCV
screening-strategy arm in the base case. Table 2 of the
Appendix in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2013.07.005 shows the unit cost of each service, as
well as their frequency in 1 year and the parameters used in the
sensitivity analysis. Costs were then discounted by 3.5%.Outcomes
Utility values with respect to complications of liver disease and
patients undergoing treatment were taken from the literature
[6,12,18]. These values were used in cost-effectiveness analyses
with reference to studies on HCV and HBV and calculated by
using the health utility index [18]. Beyond the utility score
referring to each health state included in the model, a disutility
coefﬁcient has been attributed to patients undergoingInpatient
€8.78
€69.77
€263.67
€47.77
€45.30
€14,165.30
€43.48
€300.00
€6.59 Average DRGs 191-192-
200-201
€13,784.00
€350.00
€24.00
€34.78 Average DRGs
199;201;20
€6,714.33
€340
DRG 480 €80,199.00
Table 5 – Utility values.
Health state Base-case value Estimated SE Distribution Alpha Beta Source
HCV 0.82 0.08 Beta 16.47 3.61 [12]
Compensated cirrhosis 0.78 0.08 Beta 20.35 5.74 [12]
Decompensated cirrhosis 0.65 0.07 Beta 32.96 17.75 [12]
Hepatocarcinoma 0.25 0.03 Beta 71.78 215.34 [12]
Liver transplant 0.5 0.05 Beta 47.52 47.52 [12]
Combination therapy 0.9 0.03 Beta 85.54 9.50 [6]
Viral positive 0.98 0.02 Beta 59.26 1.21 [18]
HCV, hepatitis C virus; SE, standard error.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 6 5 – 9 7 2 969combination drug therapy to represent the negative effect of ﬂu-
like symptoms induced by interferon. Moreover, a utility multi-
plier has been used in positive testing patients to represent the
disutility of being aware of their illness. The utility values used to
populate the model are reported in Table 5, together with the
parameters used in the sensitivity analysis. In the base case,
health beneﬁts were also discounted by 3.5%.
Cost-Effectiveness Ratio
The cost-effectiveness analysis of the course of general-risk
individuals undergoing HCV testing was performed by computing
its incremental cost-effectiveness ratio (ICER), deﬁned as the
incremental cost with respect to the no-screening alternative,
divided by the incremental gain in quality-adjusted life-years
(QALYs). The ICER refers only to people affected by hepatitis
because costs and QALYs have been computed only for these
individuals. It should be borne in mind, however, that the ICER
included the per capita cost of the administration of the screen-
ing test to 100,000 people, which was spread only over those
testing positive in the screening arm.
Univariate Sensitivity Analysis
The sensitivity analysis considered the variation in the cost-
effectiveness ratio induced by a change in the discount rate for
costs and beneﬁts, the drivers of costs, the HCV genotype, the
treatment cost and effectiveness, and the utility score for each
health state. For the discount rate, we checked the impact of
discounting only costs by 3%, avoiding discounting QALYs. More-
over, we considered the option of discounting costs at a 3% rate
and beneﬁts at a 1.5% rate. In the base case, we used a weighted
average of effectiveness and costs of PEG-IFN alfa 2a and 2b and
weighted values for the prevalence of genotypes. In the sensi-
tivity analysis, we assessed the impact of each drug in genotypes
1 to 4 and 2 to 3 to take into account the different effectiveness
and duration of treatments. For each health state, we used utility
values corresponding to the minimum and maximum values
found in the literature. For drivers of consumption of resources,
such as the number of visits and the number of diagnostic tests,
extreme values were determined on the basis of experts’
opinions.
We also conducted a heterogeneity analysis by using deter-
ministic variation of the age of the cohort undergoing screening.
So far, very few studies exploring the national epidemiologic
pattern of the disease in Italy have been performed. Surveys
performed either in small centers or in single regions, however,
are a lot more common. To underline the dramatic North-South
gradient in the prevalence of hepatitis C in Italy, and to inves-
tigate its impact on the model results, we performed a determin-
istic sensitivity analysis by using data from three studies
performed in three different Italian regions: Lombardia (Northern
Italy), Lazio (Central Italy), and Calabria (Southern Italy).Probabilistic Sensitivity Analysis
Themultivariate sensitivity analysis aimed to construct a set of 5000
scenarios including the simultaneous variation of all the parameters
already considered individually in the univariate analysis.
The transition probabilities and the utility data were assumed
to be in line with a random beta distribution. The conﬁdence
interval around each parameter was used to derive the standard
error and the parameters of the distribution. Whenever this
information was lacking, the conﬁdence interval was estimated
by assuming a variation of 20% to compute the extreme values.
We assigned a gamma distribution to cost drivers, namely, treat-
ment duration, number of visits, and number of follow-up exami-
nations. The probabilistic sensitivity analysis was developed on the
basis of a Monte Carlo simulation conducted by using the Excel
Poptools add-on. The scenarios obtained through the Monte Carlo
simulation were plotted on a cost-effectiveness acceptability curve
(CEAC), which indicates the model’s probabilistic response to a
threshold cost-effectiveness value, expressed in terms of cost per
QALY that a decision maker may be willing to pay.Results
Analysis of Base Case
Table 6 reports the results for the base case comparing the
screening-strategy arm against the no-screening-strategy arm.
The hypothesis was the enrolment of 100,000 people from the
general Italian population in the screening program, distributing
the cost of the screening campaign and second-level testing of
false positives over the people actually infected with HCV. The
early detection strategy costs overall €25,341 per patient, yielding
27.3 QALYs. However, the cost per patient of the no-screening
arm is €15,661 against 25.4 QALYs. Therefore, the implementa-
tion of the screening program generates an incremental cost of
€9,679 per patient against a gain of 1.87 QALYs. Costs and QALYs
refer to the proportion of patients affected by HCV. The cost of
negative test results has been spread on the proportion of
patients with positive test results in the screening arm. The ICER
of the screening strategy arm with respect to the no-screening
alternative is €5,171/QALY. This is below the threshold value
usually taken into consideration by the National Institute for
Health and Care Excellence, which ranges between £20,000 and
£30,000/QALY. In Italy, there is no set value for the cost-
effectiveness threshold yet, but according to the existing liter-
ature, about treatments that have already been approved, the
maximum cost/QALY that the INHS is willing to bear is €60,000/
QALY gained [19–21].
Sensitivity Analysis
We conducted a univariate sensitivity analysis to explore ICER
variability in relation to the age of the studied cohort undergoing
Table 6 – Heterogeneity of results with respect to age: anti-HCV screening.
Costs (€) QALYs Incremental costs (€) Incremental QALYs ICER
Base case
Screening 25,341.07 27.31
9,679.51 1.87 5,171.23
No screening 15,661.57 25.43
People aged 35 y
Screening 31,04124 31.03
3,477.65 2.51 1,384.14
No screening 27,563.59 28.51
People aged 45 y
Screening 27,688.07 28.80
7,983.94 2.01 3,971.88
No screening 19,704.13 26.79
People aged 55 y
Screening 23,540.91 23.77
11,680.99 1.49 7,829.85
No screening 11,859.92 22.28
People aged 65 y
Screening 19,525.23 25.42
15,263.43 1.46 10,432.86
No screening 4,261.80 23.96
HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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because of the different prevalence of the disease in different age
groups and their different mortality rates for other causes.
Screening of a population of 35-year-olds requires an incremental
cost of €3477 and yields a gain of 2.51 QALYs per patient. This ﬁrst
strategy is characterized by an ICER of €1384/QALY.
As soon as the age of the target population increases, the
incremental cost associated with the screening strategy raises
whereas the QALY gain drops.
The cost per QALY gained increases more than proportionally
with the age of the cohort under study. In the oldest age cohort,
the cost per QALY gained reaches €10,432 but the ICER still lies
below the level that the INHS has accepted until now [19,20].
Table 6 shows the results of the heterogeneity analysis in relation
to age groups.
We also conducted a univariate sensitivity analysis to exam-
ine the robustness of model results in case of variation of the
main parameters: discount rate, efﬁcacy of pharmacological
treatments and utility of each health state, and drivers of cost.
The model results were assessed considering 5-, 10-, 20-, 30-year,
and lifetime horizons.
Model results are not signiﬁcantly affected by the discount
rate, especially for long time horizons. The results of the one-way
analysis on discount rate are reported in Table 3 of the Appendix
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2013.07.005.
In the sensitivity analysis, the efﬁcacy value used in the base
case was replaced with values taken from the literature for each
genotype. This was done for both PEG-IFN alfa 2a and PEG-IFN
alfa 2b. The ICER for both PEG-IFN alfa 2b and PEG-IFN alfa 2a was
higher for genotypes 1 and 4, which require a longer treatment
compared with genotypes 2 and 3. PEG-IFN alfa 2a yields more
favorable ICERs in spite of the higher cost. In all cases, lower
efﬁcacy was associated with an increase in the ICER. The efﬁcacy
values considered and the relative results are reported in Table 4
of the Appendix in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2013.07.005.
The minimum and maximum utility values for each health
state were entered one at a time in the model. The results of the
model seem to be affected more by the time horizon than by the
utility values. The results of this analysis are reported in Table 5
of the Appendix in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2013.07.005.
The variation in model results due to changes in health state–
related costs was investigated by varying the annual expectednumber of procedures per patient within the range speciﬁed by
our panel of experts. The number of hospital admissions was
unchanged. The ICER increases when the cost of monitoring
HCV-affected patient increases, but changes are not signiﬁcant.
Results are shown in Table 6 of the Appendix in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.07.005.
In the deterministic sensitivity analysis, model results were
observed adopting a 5-, 10-, 20-, 30-year, and lifetime horizon.
The results were more sensitive to the time horizon than to the
variation in critical parameters: ICER decreases when the time
horizon gets longer, even though it always stays below €60,000/
QALY. This is because the National Health Service bears the
highest costs during the ﬁrst year, when the screening is
administered to the target population and patients with positive
test results receive costly drug treatments. Thus, in shorter time
horizons, even if the system has supported a big investment, only
a few beneﬁts (QALYs) have been produced, and their marginal
cost is high. Furthermore, costs in the screening arm start
decreasing from the second year on, while the total number of
QALY rises. Moreover, the effect of the discount rate is less
evident in short time horizons.
The North-South gradient in HCV prevalence is more evident in
the population aged older than 65 years. The analysis carried out
by varying the prevalence data shows that the model results are
sensitive to both age and disease prevalence in the population. In
particular, in all the scenarios it appears that the ICER tends to
increase when the population age increases, coherently with the
heterogeneity analysis. Moreover, within the same age group it is
possible to notice a slightly different ICER across people belonging
to different geographical areas in favor of the Southern cohort,
which shows the biggest prevalence. This trend occurs in all the
other age groups even though in a less evident way. Results are
fully reported in Table 7 of the Appendix in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2013.07.005.Monte Carlo Simulation
The results of the Monte Carlo simulation are summarized in
Figure 2, representing the CEAC for each age cohort and for the
full population, based on the prevalence estimates of Ansaldi
et al. [7]. Each curve represents 1,000 realizations. The probabil-
istic analysis conﬁrms that the results of the model are strongly
affected by the age group on which the screening strategy is
implemented. There are numerous cases of dominance when the
screening population is 35 years old, whereas higher or even
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 6 5 – 9 7 2 971dominated ICER values are produced in higher age groups. Values
resulting from the Monte Carlo analysis are reported in increas-
ing order along the acceptability curves shown in Figure 2. Over-
all, it can be seen that in almost all (88%) the envisaged scenarios,
the ICER remains under the threshold value of £30,000/QALY.
Furthermore, more than 85% of the scenarios are also under the
threshold of £20,000/QALY. Taking into account the threshold
value derived from Italian existing literature, almost all the
scenarios yielded by the Monte Carlo simulation can be consid-
ered affordable, being lower than €60,000/QALY gained. Although
some outcomes of the simulation predicted an ICER of more than
€200,000/QALY, the probability of occurrence of such realizations
is almost zero. As a matter of fact, when varying more parame-
ters simultaneously, they may generate contrasting effects, even
offsetting each other. The impact of age on the model results is
very clear in CEACs. For every level of prevalence, it is preferable
to screen and treat the youngest cohort. The 35-year-old aged
population presents not only the biggest percentage of domi-
nance but also the smallest variability in the ICER, which hardly
exceeds €22,000/QALY.Discussion
In this analysis, we used a Markov model to observe the long-
term progression of two hypothetical patient cohorts undergoing
two alternative diagnosis and treatment protocols for HCV
infection, quantifying the respective costs and beneﬁts. Clinical
data and information were mapped on the basis of international
guidelines [1] and experts’ opinions. Costs were quantiﬁed from
the INHS perspective.
The Markov model for the base case yielded an ICER of €5171/
QALY gained with the screening and treatment of positives
strategy, compared with the alternative of no screening and treat-
ment of symptomatic patients only. This value is deﬁnitively lower
than the cost/QALY of treatments already approved in Italy.
The robustness of the model results was evaluated with both
a univariate and a multivariate sensitivity analysis. Time hori-
zon, age, and prevalence rate are the parameters that mainly0
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Fig. 2 – CEAC. CEAC, cost-effectiveness acceptabilityaffect model results. Better results can be observed for longer
time horizons because the screening program requires an imme-
diate investment, promising health beneﬁts in the future. ICERs
are more favorable in younger cohorts especially in longer time
horizons. Probably this is due to the longer life expectancy of
younger people. Prevalence affects the results of the model too,
but not as much as the previous parameters. Higher prevalence
rates are not always associated with lower ICERs.
Our study has various limitations, mainly due to the require-
ments of simplicity and functionality. The Markov cycles used in
this study cover a time horizon of 40 years. This was chosen
because of the slow progression of hepatitis C. Over such a long
period of time, however, it is highly likely that more effective and
more expensive new diagnostic and treatment strategies will be
introduced on the market. For example, we did not consider the
introduction of boceprevir and telaprevir for genotype 1 because no
prices have been negotiated in Italy yet. Nevertheless, we adapted
this model in a recent study, removing screening and considering
the use of triple therapy in both naive and experienced patients
compared with standard therapy. We quantiﬁed the additional cost
for the new molecules starting by the cost borne by The French
Agency for Research on AIDS and Viral Hepatitis to provide
seriously ill patients with the opportunity to get an early access to
these drugs. We assumed that the triple therapy was delivered
against an average cost of €26,000 per patient. The ICER of admin-
istrating triple therapy to nonresponders compared with standard
of care resulted in around €20,000/QALY, while the ICER of triple
therapy versus double in naive patients was around €12,000/QALY.
It would have been better to perform a meta-analysis to get
more robust data about drug efﬁcacy and safety and use them to
populate the model. Nevertheless, very little evidence was found on
the comparison between PEG-IFN alfa 2a and 2b in all genotypes.
Moreover, our focus was screening and not drug administration.
Furthermore, the overhead of managing the screening program
(calls, recalls, etc.) was not included in its costs. There are
currently no structured regional mass screening programs against
viral hepatitis ongoing in Italy. This type of organizational setup
would be neither sustainable nor cost-effective, as demonstrated
in a review conducted by Sroczynski et al. [2] in 2009. For this,000 € 60,000 € 80,000
reshold
-eged people ICER 65-aged people
-aged people
curve; ICER, incremental cost-effectiveness ratio.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 6 5 – 9 7 2972reason, we considered that a key role could be played by general
practitioners, consultants, addiction services, and other primary
care workers during their normal working activities.
Having these limitations in mind, our model does have the
advantage of a high ﬂexibility: it could easily be adapted to
evaluate shifts in ICER and thus the acceptability of the hypo-
thetical strategy in clinical practice if new data are produced on
transition probabilities and/or treatment costs and efﬁcacy. This
study, which is part of the First National Workshop for Economics
and Drugs in Hepatology (Workshop Nazionale di Economia e
Farmaci in Epatologia - WEF-E 2011), also has the advantage of
drawing the attention of the scientiﬁc community to hepatitis C,
which represents a serious problem in Italy for its remarkable
prevalence [22]. The study is also based on costs and prevalence
data speciﬁcally referred to Italy, taking into account not only
efﬁcacy but also the economic sustainability of the program.Conclusions
According to our study, early diagnosis of HCV infection through
ﬁrst-level testing with enzyme immunoassay and second-level
conﬁrmation through viral RNA testing, followed by prompt treat-
ment of subjects testing positive, has a favorable ICER in the
population considered at general risk of incurring an HCV infection,
if compared with the alternative protocol of only treatment of
subjects with cirrhosis or hepatic carcinoma. This can be seen as
the ﬁrst step toward the diffusion of this practice so that general
practitioners can advise their 35-years-old patients, as well as older
ones, to undergo screening.
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